240 related articles for article (PubMed ID: 25113930)
1. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
[TBL] [Abstract][Full Text] [Related]
2. Triazolopyridazine LRRK2 kinase inhibitors.
Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
[TBL] [Abstract][Full Text] [Related]
3. Novel cinnoline-based inhibitors of LRRK2 kinase activity.
Garofalo AW; Adler M; Aubele DL; Bowers S; Franzini M; Goldbach E; Lorentzen C; Neitz RJ; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Jan; 23(1):71-4. PubMed ID: 23219325
[TBL] [Abstract][Full Text] [Related]
4. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
[TBL] [Abstract][Full Text] [Related]
5. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
[TBL] [Abstract][Full Text] [Related]
7. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
Göring S; Taymans JM; Baekelandt V; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
10. Identification of triazolopyridazinones as potent p38α inhibitors.
Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
[TBL] [Abstract][Full Text] [Related]
11. 5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.
Ding X; Stasi LP; Dai X; Long K; Peng C; Zhao B; Wang H; Sun C; Hu H; Wan Z; Jandu KS; Philps OJ; Chen Y; Wang L; Liu Q; Edge C; Li Y; Dong K; Guan X; Tattersall FD; Reith AD; Ren F
Bioorg Med Chem Lett; 2019 Jan; 29(2):212-215. PubMed ID: 30522952
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
13. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
14. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA
Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
Troxler T; Greenidge P; Zimmermann K; Desrayaud S; Drückes P; Schweizer T; Stauffer D; Rovelli G; Shimshek DR
Bioorg Med Chem Lett; 2013 Jul; 23(14):4085-90. PubMed ID: 23768909
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Pyrrolo[2,3-
Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
19. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
Estrada AA; Liu X; Baker-Glenn C; Beresford A; Burdick DJ; Chambers M; Chan BK; Chen H; Ding X; DiPasquale AG; Dominguez SL; Dotson J; Drummond J; Flagella M; Flynn S; Fuji R; Gill A; Gunzner-Toste J; Harris SF; Heffron TP; Kleinheinz T; Lee DW; Le Pichon CE; Lyssikatos JP; Medhurst AD; Moffat JG; Mukund S; Nash K; Scearce-Levie K; Sheng Z; Shore DG; Tran T; Trivedi N; Wang S; Zhang S; Zhang X; Zhao G; Zhu H; Sweeney ZK
J Med Chem; 2012 Nov; 55(22):9416-33. PubMed ID: 22985112
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
